4 active not recruiting. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Active not recruiting 4 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Ocrelizumab - Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 4 | Active not recruiting | Hoffmann-La Roche | 60 | 2025-07-04 | 2026-09-30 |
| A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis BMS-986374 - Relapsing Multiple Sclerosis | Phase 4 | Active not recruiting | Bristol-Myers Squibb | 84 | 2024-05-15 | 2025-04-16 |
| Effects of Ocrevus in Relapsing Multiple Sclerosis Ocrelizumab, Platform - Relapsing Multiple Sclerosis | Phase 4 | Active not recruiting | Georgia State University | 60 | 2021-02-05 | 2026-06-17 |
| Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset Ocrelizumab - Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Active not recruiting | University of California, San Francisco | 30 | 2020-08-30 | 2026-01-26 |
Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Multiple Sclerosis (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
ocrelizumab (3) · ozanimod (1)
Bristol-Myers Squibb (1) · Georgia State University (1) · Hoffmann-La Roche (1) · University of California, San Francisco (1)
China (2) · United States (2)
Bruce Cree, MD, PhD, MAS (1) · Feng Yang, PhD (1)